4.7 Article

RGD-peptide conjugated inulin-ibuprofen nanoparticles for targeted delivery of Epirubicin

Journal

COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 144, Issue -, Pages 81-89

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2016.03.077

Keywords

Drug delivery; RGD; Target; Epirubicin; Nanoparticle

Funding

  1. Natural Science Foundation of Jiangsu Province of China [BK20130390, BK20140429]
  2. National Natural Science Foundation of China [81401796, 31500782, 81371687]
  3. Priority of Academic Program Development of Jiangsu Higher Education Institutions
  4. Innovation Talent Fund of Nantong University [CXZR201507, YXY201512]

Ask authors/readers for more resources

Recently, chemotherapy-based polymeric nanoparticles have been extensively investigated for solid tumor treatment. Tumor targeted nanoparticles demonstrated great potential for improved accumulation in the tumor tissue, superior anticancer activity and reduced side effects. Thus, inulin-ibuprofen polymer was synthesized by esterification between inulin and ibuprofen, and RGD targeted epirubicin (EPB) loaded nanoparticles were prepared by the self-assembly of inulin-ibuprofen polymer and in situ encapsulation of EPB. RGD conjugated EPB loaded nanoparticles were characterized by dynamic light scattering (DLS) and transmission electron microscope (TEM). The EPB release from the nanoparticles showed pH-dependent profile and accelerated by the decreased pH value, which would favor the effective drug delivery in vivo. Intracellular uptake analysis suggested that RGD conjugated nanoparticles could be easily internalized by the cancer cells. In vitro cytotoxicity revealed that RGD conjugated EPB loaded nanoparticles exhibited the better antitumor efficacy compared with non-conjugated nanoparticles. More importantly, RGD conjugated EPB loaded nanoparticles showed superior anticancer effects and reduced toxicity than free EPB and non-conjugated nanoparticles by in vivo antitumor activity, EPB biodistribution and histology analysis. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available